Bristol-Myers and AbbVie Speed Toward FDA Approval With a 'Breakthrough' Cancer Drug

Tuesday, September 1, 2015

Source: Fierce Biotech

A new drug for blood cancer from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV) is on the fast track to FDA approval, winning a priority review to treatmultiple myeloma.

The antibody, elotuzumab, is designed to train the immune system's attention on a protein called SLAMF7, expressed by tumor cells that might otherwise go unnoticed by the body's natural defenses. With the priority review tag, the agency promises to give Bristol-Myers and AbbVie a final decision within 6 months, shortening the standard 10-month time frame.

View All News »